ムーンレイク・イミュノセラピューティクス
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.84 | $0 | -$56M |
| 2026 Q1 | -0.98 | $0 | -$66M |
| 2025 Q4 | -0.93 | $0 | -$59M |
| 2025 Q3 | -1.10 | $0 | -$45M |
| 2025 Q2 | -0.87 | $0 | -$55M |
| 2025 Q1 | -0.63 | $0 | -$38M |
| 2024 Q4 |
| -0.72 |
| $0 |
| -$49M |
| 2024 Q3 | -0.56 | $0 | -$25M |